pioglitazone has been researched along with glimepiride in 100 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 40 (40.00) | 29.6817 |
| 2010's | 51 (51.00) | 24.3611 |
| 2020's | 9 (9.00) | 2.80 |
| Authors | Studies |
|---|---|
| Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ | 1 |
| Afshari, CA; Eschenberg, M; Hamadeh, HK; Lee, PH; Lightfoot-Dunn, R; Morgan, RE; Qualls, CW; Ramachandran, B; Trauner, M; van Staden, CJ | 1 |
| Ekins, S; Williams, AJ; Xu, JJ | 1 |
| Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V | 1 |
| Cantin, LD; Chen, H; Kenna, JG; Noeske, T; Stahl, S; Walker, CL; Warner, DJ | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Aleo, MD; Bonin, PD; Luo, Y; Potter, DM; Swiss, R; Will, Y | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Jones, LH; Nadanaciva, S; Rana, P; Will, Y | 1 |
| Dowarah, J; Singh, VP | 1 |
| Antúnez, O; Fabián, G; Flores-Lozano, F; Garza, E; González Gálvez, G; Herz, M; Johns, D; Konkoy, C; Morales, H; Tan, M; Zúñiga Guajardo, S | 1 |
| Bertone, G; Ciccarelli, L; Cicero, AF; Derosa, G; Fogari, E; Gaddi, A; Piccinni, MN; Ragonesi, PD | 1 |
| Ramachandran, A; Salini, J; Snehalatha, C; Vijay, V | 1 |
| Ciccarelli, L; Cicero, AF; Derosa, G; Fogari, E; Fogari, R; Gaddi, A; Piccinni, MN; Ragonesi, PD; Salvadeo, S | 1 |
| Forst, T; Konrad, T; Langenfeld, M; Lübben, G; Marx, N; Pfützner, A; Walcher, D | 1 |
| Ichiyanagi, K; Igarashi, K; Kawasaki, T; Sakai, T; Watanabe, H; Yamanouchi, T | 1 |
| Forst, T; Hohberg, C; Kann, P; Lübben, G; Pahler, S; Pfützner, A; Pfützner, AH | 1 |
| Forst, T; Fuellert, SD; Gottschall, V; Hohberg, C; Konrad, T; Löbig, M; Lübben, G; Pfützner, A; Sachara, C; Weber, MM | 1 |
| Issa, M; Lake, B; Melis, R; Roberts, VL; Stewart, J | 1 |
| Chopra, D; Kinagi, SB; Langade, DG; Meshram, DM; Morye, V; Naikwadi, AA | 1 |
| Ciccarelli, L; Cicero, AF; Dangelo, A; Derosa, G; Ferrari, I; Fogari, R; Gaddi, A; Ghelfi, M; Montagna, L; Piccinni, MN; Pricolo, F; Ragonesi, PD; Salvadeo, S | 1 |
| Issa, M; Umpierrez, G; Vlajnic, A | 1 |
| Ciccarelli, L; Cicero, AF; D'Angelo, A; Derosa, G; Ferrari, I; Gaddi, A; Gravina, A; Piccinni, MN; Pricolo, F; Ragonesi, PD; Salvadeo, SA | 1 |
| D'Agostino, RB; Davidson, MH; Feinstein, SB; Haffner, SM; Kondos, GT; Mazzone, T; Meyer, PM; Perez, A; Provost, JC | 1 |
| Esposito, K; Giugliano, D | 1 |
| Kida, Y; Sato, T | 1 |
| Armbruster, FP; Borchert, M; Forst, T; Grabellus, M; Hohberg, C; Köder, C; Löbig, M; Lübben, G; Pfützner, A; Roth, W; Schöndorf, T | 1 |
| Bradford, D; Karim, A; Laurent, A; Schuster, J; Slater, M; Zhao, Z | 1 |
| Derosa, G | 1 |
| Armbruster, FP; Borchert, M; Forst, T; Grabellus, M; Hohberg, C; Hoopmann, M; Löbig, M; Lübben, G; Pfützner, A; Roth, W; Schöndorf, T | 1 |
| Blake, EW | 1 |
| Dorkhan, M; Frid, A | 1 |
| De Larochellière, R; Hu, B; Jure, H; Kupfer, S; Lincoff, AM; Mavromatis, K; Nesto, R; Nicholls, SJ; Nissen, SE; Perez, A; Saw, J; Staniloae, CS; Tuzcu, EM; Wolski, K | 1 |
| Marre, M; Steg, PG | 1 |
| Chen, Z; D'Agostino, R; Davidson, M; Feinstein, S; Haffner, S; Kondos, GT; Mazzone, T; Meyer, PM; Perez, A | 1 |
| Amin, M; Jain, D; Jain, S | 1 |
| Shah, R | 1 |
| Fresco, C | 1 |
| Birnbaum, Y; Lin, Y; Perez-Polo, JR; Ye, Y | 1 |
| A, K; A, R; Bhat, K; C, MR; G, S; K, K; M, S; N, U; P, M | 1 |
| Kanioglou, C; Katsouras, CS; Kazakos, N; Kolettis, T; Liveris, K; Makriyiannis, D; Michalis, LK; Naka, KK; Papathanassiou, K; Pappas, K; Tsatsoulis, A | 1 |
| Akishita, M; Lisanti, MP; Okamoto, L; Okamoto, T | 1 |
| Bax, JJ; de Jong, HW; de Roos, A; Diamant, M; Heine, RJ; Kamp, O; Lamb, HJ; Lammertsma, AA; Lubberink, M; Paulus, WJ; Rijzewijk, LJ; Romijn, JA; Smit, JW; van der Meer, RW | 1 |
| Gropler, RJ | 1 |
| Cicero, AF; D'Angelo, A; Derosa, G; Ferrari, I; Gravina, A; Maffioli, P; Mereu, R; Palumbo, I; Salvadeo, SA | 1 |
| Chawla, S; Chogtu, B; Gupta, U; Singh, NP | 1 |
| Borchert, M; Forst, T; Hohberg, C; Karagiannis, E; Lübben, G; Pfützner, A; Schöndorf, T | 1 |
| Davidson, M; Mazzone, T; Polonsky, T | 1 |
| de Haan, W; de Roos, A; Diamant, M; Jonker, JT; Lamb, HJ; Rensen, PC; Rijzewijk, LJ; Romijn, JA; Smit, JW; Tamsma, JT; van der Meer, RW; Wang, Y | 1 |
| Forst, T; Friedrich, C; Fuchs, W; Hohberg, C; Lehmann, U; Löbig, M; Müller, J; Pfützner, A; Weber, MM | 1 |
| Ciccarelli, L; D'Angelo, A; Derosa, G; Ferrari, I; Franzetti, IG; Gadaleta, G; Maffioli, P; Mereu, R; Piccinni, MN; Querci, F; Ragonesi, PD; Salvadeo, SA | 1 |
| Beam, CA; D'Agostino, R; Davidson, MH; Haffner, S; Mazzone, T; Perez, A | 1 |
| Blümner, E; Derwahl, M; Forst, T; Fuchs, W; Hohberg, C; Jacob, S; Lehmann, U; Pfützner, A | 1 |
| Ali, S; Imran, A; Rao, DK; Shaik, JP; Shaik, NA | 1 |
| Chen, Y; Hu, YY; Wu, FZ; Ye, SD; Zhao, LL; Zheng, M | 1 |
| Boulton, DW; Griffen, SC; Kasichayanula, S; LaCreta, FP; Li, T; Liu, X; Pfister, M; Shyu, WC; Zhang, W | 1 |
| Deshpande, PB; Karthik, A; Musmade, PB; Pandey, S; Pathak, SM; Talole, KB; Udupa, N | 1 |
| Forst, T; Fuchs, W; Lehmann, U; Lobmann, R; Merke, J; Müller, J; Pfützner, A; Schöndorf, T; Tschöpe, D | 1 |
| Bell, DS; Dharmalingam, M; Kumar, S; Sawakhande, RB | 1 |
| Forst, T; Fuchs, W; Hohberg, C; Lehmann, U; Löbig, M; Müller, J; Musholt, PB; Pfützner, A; Schöndorf, T | 1 |
| Harada, H; Hayabuchi, N; Ikeda, H; Imaizumi, T; Ishibashi, M; Kaida, H; Kodama, N; Mawatari, K; Mizoguchi, M; Nitta, Y; Oba, T; Tahara, A; Tahara, N; Yamagishi, S; Yasukawa, H | 1 |
| Finn, AV; Tawakol, A | 1 |
| Marwick, TH; Narula, J | 1 |
| Bechlioulis, A; Kanioglou, C; Kazakos, N; Kostoula, A; Makriyiannis, D; Michalis, LK; Naka, KK; Papathanassiou, K; Pappas, K; Tsatsoulis, A; Vezyraki, P | 1 |
| Jermendy, G | 1 |
| D'Agostino, R; Davidson, MH; Haffner, S; Mazzone, T; Perez, A; Sam, S | 1 |
| Kadokura, T; Keirns, J; Krauwinkel, WJ; Smulders, RA; van Dijk, J; Veltkamp, SA; Zhang, W | 1 |
| Komiyama, N | 1 |
| Bhansali, A; Sachdeva, N; Sridhar, S; Walia, R | 1 |
| Dressman, JB; Klein, S; Taupitz, T | 1 |
| Hirayama, M; Hiroi, S; Kaku, K; Kawakami, K; Kuriyama, K; Matsuno, K; Sugiura, K | 1 |
| Anderwald, CH; Bernroider, E; Brehm, A; Krebs, M; Krssak, M; Nowotny, P; Phielix, E; Roden, M; Schmid, AI | 1 |
| Imaizumi, T; Mizoguchi, M; Tahara, A; Tahara, N; Yamagishi, S | 1 |
| Abe, T; Fukumoto, Y; Honda, A; Ikeda, H; Imaizumi, T; Ishibashi, M; Kaida, H; Kodama, N; Mizoguchi, M; Narula, J; Nitta, Y; Tahara, A; Tahara, N; Yamagishi, S | 1 |
| Gao, L; Riddle, MC; Rosenstock, J; Vlajnic, A | 1 |
| Hayabuchi, N; Honda, A; Ikeda, H; Imaizumi, T; Ishibashi, M; Kaida, H; Kodama, N; Mizoguchi, M; Nitta, Y; Tahara, A; Tahara, N; Yamagishi, S | 1 |
| Agrawal, N; Bhandari, S; Chandurkar, N; Deshpande, A; Devaramani, S; Gupta, OP; Kakrani, A; Kothari, K; Mahesh, M; Pareek, A; Saboo, B; Shah, A; Sharma, S; Thomas, N; Thulasidharan, NK; Vijaykumar, NB; Viswanathan, V | 1 |
| Emoto, M; Fujii, H; Fukui, M; Fukumoto, S; Inaba, M; Koyama, H; Monden, M; Mori, K; Morioka, T; Nishizawa, Y; Shoji, T; Tanaka, S | 1 |
| Hu, JQ; Ni, XJ; Qiu, C; Shang, DW; Wang, ZZ; Wen, YG; Zhang, M | 1 |
| Carr, MC; Home, PD; Miller, M; Perry, C; Shamanna, P; Stewart, M; Yang, F | 1 |
| Nagai, Y | 1 |
| Fukatsu, A; Sakai, S; Samukawa, Y; Sasaki, T; Seino, Y; Ubukata, M | 1 |
| Fukase, H; Harigai, M; Iida, S; Ikeda, S; Kasahara, N; Miyata, K; Ohba, Y; Saito, T; Takano, Y; Terao, K | 1 |
| El-Zaher, AA; Elkady, EF; Elwy, HM; Saleh, MA | 1 |
| El-Zaher, AA; Elkady, EF; Elwy, HM; Saleh, MAEM | 1 |
| Ahrén, B; Ambery, P; Carr, MC; Cirkel, DT; Home, PD; Miller, D; Nauck, MA; Rendell, M; Reusch, JEB; Weissman, PN | 1 |
| Cardoso, AA; da Silveira Petruci, JF; Hauser, PC; Liebetanz, MG | 1 |
| Chen, SH; Liu, XN; Peng, Y; Sun, QY | 1 |
| Abdel Salam, RA; Abdelhady, KK; El-Wekil, MM; Hadad, GM | 1 |
| Burlina, S; Chilelli, NC; Cosma, C; Lapolla, A; Marin, R; Ragazzi, E; Roverso, M; Sartore, G; Seraglia, R; Vaccaro, O | 1 |
| Avdeef, A; Barbas, R; Lucero-Borja, D; Prohens, R; Ràfols, C; Subirats, X | 1 |
| Akhter, R; Halim, MA; Md Opo, FAD; Nasreen, W; Sarker, S; Shahriar, M; Sufian, MA | 1 |
| Fushimi, Y; Hirata, Y; Hirukawa, H; Irie, S; Kaku, K; Kaneto, H; Kimura, T; Kinoshita, T; Kohara, K; Mune, T; Nakamura, Y; Nakanishi, S; Nakashima, K; Nishioka, M; Obata, A; Sanada, J; Shimoda, M; Tanabe, A; Tatsumi, F | 1 |
| Chen, FW; Hou, KJ; Khan, BA; Wu, Z; Wu, ZZ; Zhang, S | 1 |
| Atta, MY; Ghoniem, NS; Hegazy, MA; Hussien, EM | 1 |
| Choi, SH; Chun, SW; Hur, KY; Jeong, IK; Kang, ES; Kim, HJ; Kim, SK; Noh, JH; Rhee, EJ | 1 |
| Elkhodary, MM; Hammad, SF; Kamal, AH; Marie, AA; Salim, MM | 1 |
| Jannetto, PJ; Langman, LJ | 1 |
9 review(s) available for pioglitazone and glimepiride
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Anti-diabetic drugs recent approaches and advancements.
Topics: Diabetes Mellitus; Dose-Response Relationship, Drug; Humans; Hypoglycemic Agents; Molecular Structure; Structure-Activity Relationship | 2020 |
Pioglitazone plus glimepiride: a promising alternative in metabolic control.
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Drug Combinations; Humans; Hypoglycemic Agents; Lipids; Patient Compliance; Pioglitazone; Sulfonylurea Compounds; Thiazolidinediones | 2007 |
Pioglitazone hydrochloride/glimepiride.
Topics: Diabetes Mellitus, Type 2; Drug Combinations; Humans; Hypoglycemic Agents; Pioglitazone; Sulfonylurea Compounds; Thiazolidinediones | 2007 |
A review of pioglitazone HCL and glimepiride in the treatment of type 2 diabetes.
Topics: Animals; Blood Glucose; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Humans; Pioglitazone; Sulfonylurea Compounds; Thiazolidinediones | 2007 |
The clinical implications of the CHICAGO study for the management of cardiovascular risk in patients with type 2 diabetes mellitus.
Topics: Carotid Arteries; Chicago; Cholesterol, HDL; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Humans; Hypoglycemic Agents; Pioglitazone; Randomized Controlled Trials as Topic; Sulfonylurea Compounds; Thiazolidinediones; Tunica Intima | 2009 |
[Incretin-based therapy for treating patients with type 2 diabetes].
Topics: Adamantane; Body Mass Index; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Drug Approval; Drug Therapy, Combination; Exenatide; Gliclazide; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Glycated Hemoglobin; Humans; Hungary; Hypoglycemic Agents; Incretins; Linagliptin; Liraglutide; Metformin; Nitriles; Peptides; Pioglitazone; Purines; Pyrazines; Pyrrolidines; Quinazolines; Receptors, Glucagon; Sitagliptin Phosphate; Sulfonylurea Compounds; Thiazolidinediones; Triazoles; Venoms; Vildagliptin | 2011 |
[PERISCOPE (Pioglitazone Effect on Regression of Intravascular Sonographic Coronary Obstruction Prospective Evaluation) trial].
Topics: Acute Coronary Syndrome; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Pioglitazone; Plaque, Atherosclerotic; Sulfonylurea Compounds; Thiazolidinediones | 2011 |
Efficacy of different antidiabetic drugs based on metformin in the treatment of type 2 diabetes mellitus: A network meta-analysis involving eight eligible randomized-controlled trials.
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Drug Combinations; Exenatide; Female; Glyburide; Humans; Male; Metformin; Network Meta-Analysis; Pioglitazone; Randomized Controlled Trials as Topic; Rosiglitazone; Sulfonylurea Compounds; Vildagliptin | 2019 |
56 trial(s) available for pioglitazone and glimepiride
| Article | Year |
|---|---|
Effects of pioglitazone and glimepiride on glycemic control and insulin sensitivity in Mexican patients with type 2 diabetes mellitus: A multicenter, randomized, double-blind, parallel-group trial.
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Lipids; Male; Mexico; Middle Aged; Pioglitazone; Sulfonylurea Compounds; Thiazolidinediones | 2004 |
Metabolic effects of pioglitazone and rosiglitazone in patients with diabetes and metabolic syndrome treated with glimepiride: a twelve-month, multicenter, double-blind, randomized, controlled, parallel-group trial.
Topics: Adult; Aged; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Lipids; Male; Metabolic Syndrome; Middle Aged; Pioglitazone; Rosiglitazone; Sulfonylurea Compounds; Thiazolidinediones | 2004 |
Use of glimepiride and insulin sensitizers in the treatment of type 2 diabetes--a study in Indians.
Topics: Adult; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; India; Insulin; Insulin Resistance; Insulin Secretion; Male; Metformin; Middle Aged; Pioglitazone; Sulfonylurea Compounds; Thiazolidinediones | 2004 |
A comparison of the effects of pioglitazone and rosiglitazone combined with glimepiride on prothrombotic state in type 2 diabetic patients with the metabolic syndrome.
Topics: Aged; Blood Pressure; Body Size; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Hypoglycemic Agents; Insulin; Male; Metabolic Syndrome; Middle Aged; Pioglitazone; Postprandial Period; Rosiglitazone; Sulfonylurea Compounds; Thiazolidinediones; Treatment Outcome; Triglycerides | 2005 |
Improvement of cardiovascular risk markers by pioglitazone is independent from glycemic control: results from the pioneer study.
Topics: Acute-Phase Proteins; Aged; Arteriosclerosis; Biomarkers; Blood Coagulation Factors; Blood Glucose; Carotid Arteries; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Male; Middle Aged; Pioglitazone; Prospective Studies; Risk Factors; Sulfonylurea Compounds; Thiazolidinediones; Tunica Intima; Tunica Media; Ultrasonography | 2005 |
Comparison of metabolic effects of pioglitazone, metformin, and glimepiride over 1 year in Japanese patients with newly diagnosed Type 2 diabetes.
Topics: Aged; Asian People; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Fasting; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Lipids; Male; Metformin; Middle Aged; Pioglitazone; Sulfonylurea Compounds; Thiazolidinediones | 2005 |
Pioneer study: PPARgamma activation results in overall improvement of clinical and metabolic markers associated with insulin resistance independent of long-term glucose control.
Topics: Biomarkers; Blood Glucose; Case-Control Studies; Humans; Hypoglycemic Agents; Insulin Resistance; Insulin-Secreting Cells; Monitoring, Physiologic; Pilot Projects; Pioglitazone; PPAR gamma; Prospective Studies; Sulfonylurea Compounds; Thiazolidinediones | 2005 |
Pharmacological PPARgamma stimulation in contrast to beta cell stimulation results in an improvement in adiponectin and proinsulin intact levels and reduces intima media thickness in patients with type 2 diabetes.
Topics: Aged; Atherosclerosis; Biomarkers; Carotid Arteries; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Insulin-Secreting Cells; Male; Middle Aged; Pioglitazone; PPAR gamma; Proinsulin; Risk Factors; Sulfonylurea Compounds; Thiazolidinediones; Tunica Intima | 2005 |
Triple therapy with glimepiride in patients with type 2 diabetes mellitus inadequately controlled by metformin and a thiazolidinedione: results of a 30-week, randomized, double-blind, placebo-controlled, parallel-group study.
Topics: Adult; Aged; Blood Glucose; Body Mass Index; C-Peptide; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Lipids; Male; Metformin; Middle Aged; Pioglitazone; Rosiglitazone; Sulfonylurea Compounds; Thiazolidinediones; Time Factors | 2005 |
Evaluation of efficacy and safety of fixed dose combination of glimepiride 2 mg pluspioglitazone 15 mg plus metformin SR 500 mg in the management of patients with type-2 diabetes mellitus.
Topics: Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Humans; Hypoglycemic Agents; Metformin; Middle Aged; Pioglitazone; Sulfonylurea Compounds; Thiazolidinediones | 2005 |
Thiazolidinedione effects on blood pressure in diabetic patients with metabolic syndrome treated with glimepiride.
Topics: Blood Glucose; Blood Pressure; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Middle Aged; Pioglitazone; Rosiglitazone; Sulfonylurea Compounds; Thiazolidinediones | 2005 |
Glimepiride versus pioglitazone combination therapy in subjects with type 2 diabetes inadequately controlled on metformin monotherapy: results of a randomized clinical trial.
Topics: Adolescent; Adult; Aged; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Pioglitazone; Sulfonylurea Compounds; Thiazolidinediones; Treatment Outcome | 2006 |
Effects of 1 year of treatment with pioglitazone or rosiglitazone added to glimepiride on lipoprotein (a) and homocysteine concentrations in patients with type 2 diabetes mellitus and metabolic syndrome: a multicenter, randomized, double-blind, controlled
Topics: Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Glycated Hemoglobin; Homocystine; Humans; Hypoglycemic Agents; Lipoproteins; Male; Metabolic Syndrome; Middle Aged; Pioglitazone; Rosiglitazone; Sulfonylurea Compounds; Thiazolidinediones | 2006 |
Effect of pioglitazone compared with glimepiride on carotid intima-media thickness in type 2 diabetes: a randomized trial.
Topics: Adult; Aged; Aged, 80 and over; Cardiovascular Diseases; Carotid Arteries; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Humans; Hypoglycemic Agents; Male; Middle Aged; Pioglitazone; Sulfonylurea Compounds; Thiazolidinediones; Tunica Intima; Ultrasonography | 2006 |
Relaxin expression correlates significantly with serum changes in VEGF in response to antidiabetic treatment in male patients with type 2 diabetes mellitus.
Topics: Aged; Biomarkers; Cohort Studies; Diabetes Mellitus, Type 2; Endothelium, Vascular; Humans; Hypoglycemic Agents; Intercellular Adhesion Molecule-1; Male; Middle Aged; Pioglitazone; Relaxin; Sulfonylurea Compounds; Thiazolidinediones; Time Factors; Vascular Cell Adhesion Molecule-1; Vascular Endothelial Growth Factor A | 2007 |
Replicate study design in bioequivalency assessment, pros and cons: bioavailabilities of the antidiabetic drugs pioglitazone and glimepiride present in a fixed-dose combination formulation.
Topics: Adolescent; Adult; Area Under Curve; Biological Availability; Cross-Over Studies; Drug Combinations; Drug Therapy, Combination; Female; Humans; Hypoglycemic Agents; Male; Middle Aged; Pioglitazone; Sex Factors; Sulfonylurea Compounds; Therapeutic Equivalency; Thiazolidinediones | 2007 |
Relaxin expression correlates significantly with serum fibrinogen variation in response to antidiabetic treatment in women with type 2 diabetes mellitus.
Topics: Administration, Oral; Adult; Aged; Diabetes Mellitus, Type 2; Enzyme-Linked Immunosorbent Assay; Female; Fibrinogen; Humans; Hypoglycemic Agents; Male; Middle Aged; Nephelometry and Turbidimetry; Pioglitazone; Relaxin; Sex Factors; Sulfonylurea Compounds; Thiazolidinediones | 2007 |
Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes: the PERISCOPE randomized controlled trial.
Topics: Aged; Atherosclerosis; Coronary Vessels; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Humans; Hypoglycemic Agents; Male; Middle Aged; Pioglitazone; Sulfonylurea Compounds; Thiazolidinediones; Ultrasonography, Interventional | 2008 |
Increased high-density lipoprotein cholesterol predicts the pioglitazone-mediated reduction of carotid intima-media thickness progression in patients with type 2 diabetes mellitus.
Topics: Aged; Carotid Arteries; Carotid Artery Diseases; Cholesterol, HDL; Diabetes Mellitus, Type 2; Disease Progression; Female; Humans; Hypoglycemic Agents; Male; Middle Aged; Pioglitazone; Predictive Value of Tests; Risk Factors; Sulfonylurea Compounds; Thiazolidinediones; Tunica Intima; Tunica Media | 2008 |
Pioglitazone vs glimepiride: Differential effects on vascular endothelial function in patients with type 2 diabetes.
Topics: Aged; Blood Glucose; Diabetes Mellitus, Type 2; Endothelium, Vascular; Female; Humans; Hypoglycemic Agents; Insulin Resistance; Male; Metformin; Middle Aged; Pioglitazone; Sulfonylurea Compounds; Thiazolidinediones; Treatment Outcome | 2009 |
Switch to oral hypoglycemic agent therapy from insulin injection in patients with type 2 diabetes.
Topics: Administration, Oral; Aged; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Inositol; Insulin; Male; Middle Aged; Pioglitazone; Sulfonylurea Compounds; Thiazolidinediones; Treatment Outcome | 2008 |
Pioglitazone improves cardiac function and alters myocardial substrate metabolism without affecting cardiac triglyceride accumulation and high-energy phosphate metabolism in patients with well-controlled type 2 diabetes mellitus.
Topics: Adenosine Triphosphate; Aged; Diabetes Complications; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Fatty Acids; Glycated Hemoglobin; Heart; Humans; Hypoglycemic Agents; Insulin Resistance; Liver; Male; Metabolic Syndrome; Metformin; Middle Aged; Myocardium; Phosphocreatine; Pioglitazone; PPAR alpha; Radionuclide Imaging; Stroke Volume; Sulfonylurea Compounds; Thiazolidinediones; Triglycerides; Ventricular Dysfunction, Left; Ventricular Remodeling | 2009 |
Direct comparison among oral hypoglycemic agents and their association with insulin resistance evaluated by euglycemic hyperinsulinemic clamp: the 60's study.
Topics: Administration, Oral; Adult; Aged; Blood Glucose; Body Mass Index; Caloric Restriction; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Exercise; Female; Glucose Clamp Technique; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Male; Metformin; Middle Aged; Motor Activity; Patient Education as Topic; Pioglitazone; Sulfonylurea Compounds; Thiazolidinediones; Time Factors; Weight Loss; Young Adult | 2009 |
Impact of glitazones on metabolic and haemodynamic parameters in patients with type 2 diabetes mellitus.
Topics: Adult; Aged; Blood Glucose; Blood Pressure; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; India; Lipids; Male; Middle Aged; Pioglitazone; Rosiglitazone; Sulfonylurea Compounds; Thiazolidinediones; Treatment Outcome | 2009 |
Pioglitazone decreases plasma cholesteryl ester transfer protein mass, associated with a decrease in hepatic triglyceride content, in patients with type 2 diabetes.
Topics: Apolipoprotein B-100; Cholesterol; Cholesterol Ester Transfer Proteins; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypoglycemic Agents; Liver; Magnetic Resonance Imaging; Male; Metformin; Middle Aged; Pioglitazone; Placebos; Prospective Studies; Sulfonylurea Compounds; Thiazolidinediones; Triglycerides | 2010 |
Pioglitazone in addition to metformin improves erythrocyte deformability in patients with Type 2 diabetes mellitus.
Topics: Adult; Aged; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Erythrocyte Deformability; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Pioglitazone; Stress, Mechanical; Sulfonylurea Compounds; Thiazolidinediones | 2010 |
Effects of one year treatment of vildagliptin added to pioglitazone or glimepiride in poorly controlled type 2 diabetic patients.
Topics: Adamantane; Body Mass Index; Body Weight; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Humans; Hypoglycemic Agents; Inflammation; Insulin Resistance; Insulin-Secreting Cells; Male; Middle Aged; Nitriles; Pioglitazone; Pyrrolidines; Sulfonylurea Compounds; Thiazolidinediones; Time Factors; Treatment Outcome; Tumor Necrosis Factor-alpha; Vildagliptin | 2010 |
Pioglitazone versus glimepiride on coronary artery calcium progression in patients with type 2 diabetes mellitus: a secondary end point of the CHICAGO study.
Topics: Aged; Calcinosis; Carotid Artery Diseases; Chi-Square Distribution; Coronary Artery Disease; Diabetes Mellitus, Type 2; Disease Progression; Female; Humans; Hypoglycemic Agents; Male; Middle Aged; Pioglitazone; Risk Assessment; Risk Factors; Sulfonylurea Compounds; Thiazolidinediones; Time Factors; Tomography, X-Ray Computed; Treatment Outcome; Ultrasonography | 2010 |
Limitations of the HOMA-B score for assessment of beta-cell functionality in interventional trials-results from the PIOglim study.
Topics: Adult; Aged; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Hypoglycemic Agents; Insulin Resistance; Insulin-Secreting Cells; Male; Middle Aged; Patient Selection; Pioglitazone; Prospective Studies; Sulfonylurea Compounds; Thiazolidinediones; Treatment Outcome | 2010 |
Hydrochloride pioglitazone decreases urinary cytokines excretion in type 2 diabetes.
Topics: Adult; Albuminuria; Blood Glucose; Blood Pressure; Chemokine CCL2; Creatinine; Cytokines; Diabetes Mellitus, Type 2; Enzyme-Linked Immunosorbent Assay; Female; Gliclazide; Humans; Hypoglycemic Agents; Male; Middle Aged; Pioglitazone; Sulfonylurea Compounds; Thiazolidinediones; Transforming Growth Factor beta1; Vascular Endothelial Growth Factor A | 2010 |
Lack of pharmacokinetic interaction between dapagliflozin, a novel sodium-glucose transporter 2 inhibitor, and metformin, pioglitazone, glimepiride or sitagliptin in healthy subjects.
Topics: Adolescent; Adult; Benzhydryl Compounds; Cross-Over Studies; Drug Interactions; Drug Therapy, Combination; Female; Glucosides; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Pioglitazone; Pyrazines; Sitagliptin Phosphate; Sodium-Glucose Transporter 2; Sulfonylurea Compounds; Thiazolidinediones; Treatment Outcome; Triazoles; Young Adult | 2011 |
PIOfix-study: effects of pioglitazone/metformin fixed combination in comparison with a combination of metformin with glimepiride on diabetic dyslipidemia.
Topics: Adiponectin; Aged; Anticholesteremic Agents; C-Reactive Protein; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Combinations; Dyslipidemias; Female; Humans; Hyperglycemia; Hypoglycemic Agents; Insulin Resistance; Male; Metformin; Middle Aged; Pioglitazone; Proinsulin; Sulfonylurea Compounds; Thiazolidinediones; Triglycerides | 2011 |
Triple oral fixed-dose diabetes polypill versus insulin plus metformin efficacy demonstration study in the treatment of advanced type 2 diabetes (TrIED study-II).
Topics: Blood Glucose; C-Peptide; Diabetes Mellitus, Type 2; Drug Combinations; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Patient Satisfaction; Pioglitazone; Postprandial Period; Prospective Studies; Sulfonylurea Compounds; Thiazolidinediones; Treatment Outcome | 2011 |
The fixed combination of pioglitazone and metformin improves biomarkers of platelet function and chronic inflammation in type 2 diabetes patients: results from the PIOfix study.
Topics: Aged; Biomarkers; Blood Coagulation; Blood Platelets; Body Mass Index; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Inflammation; Ligands; Male; Metformin; Middle Aged; Pioglitazone; Platelet Function Tests; Sulfonylurea Compounds; Thiazolidinediones; Thromboxanes; von Willebrand Factor | 2011 |
Pioglitazone attenuates atherosclerotic plaque inflammation in patients with impaired glucose tolerance or diabetes a prospective, randomized, comparator-controlled study using serial FDG PET/CT imaging study of carotid artery and ascending aorta.
Topics: Aged; Anti-Inflammatory Agents; Aortic Diseases; Aortography; Biomarkers; Blood Glucose; C-Reactive Protein; Carotid Artery Diseases; Cholesterol, HDL; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Fluorodeoxyglucose F18; Glucose Intolerance; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Inflammation; Japan; Male; Middle Aged; Multimodal Imaging; Pioglitazone; Positron-Emission Tomography; Predictive Value of Tests; Prospective Studies; Radiopharmaceuticals; Regression Analysis; Sulfonylurea Compounds; Thiazolidinediones; Time Factors; Tomography, X-Ray Computed; Treatment Outcome | 2011 |
Effects of pioglitazone and metformin on vascular endothelial function in patients with type 2 diabetes treated with sulfonylureas.
Topics: Aged; Biomarkers; Brachial Artery; Chi-Square Distribution; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Endothelium, Vascular; Female; Glycated Hemoglobin; Greece; Humans; Hypoglycemic Agents; Insulin; Male; Metformin; Middle Aged; Pioglitazone; Sulfonylurea Compounds; Thiazolidinediones; Time Factors; Treatment Outcome; Ultrasonography, Doppler; Vasodilation | 2012 |
Pioglitazone-mediated changes in lipoprotein particle composition are predicted by changes in adiponectin level in type 2 diabetes.
Topics: Adiponectin; Aged; Aged, 80 and over; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Humans; Hypoglycemic Agents; Lipid Metabolism; Lipoproteins; Male; Middle Aged; Molecular Weight; Pioglitazone; Prognosis; Sulfonylurea Compounds; Thiazolidinediones | 2012 |
No pharmacokinetic interaction between ipragliflozin and sitagliptin, pioglitazone, or glimepiride in healthy subjects.
Topics: Adolescent; Adult; Area Under Curve; Body Mass Index; Cross-Over Studies; Diabetes Mellitus, Type 2; Drug Interactions; Drug Therapy, Combination; Female; Glucosides; Humans; Hypoglycemic Agents; Male; Middle Aged; Pioglitazone; Pyrazines; Sitagliptin Phosphate; Sulfonylurea Compounds; Thiazolidinediones; Thiophenes; Triazoles | 2012 |
[PERISCOPE (Pioglitazone Effect on Regression of Intravascular Sonographic Coronary Obstruction Prospective Evaluation) trial].
Topics: Acute Coronary Syndrome; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Pioglitazone; Plaque, Atherosclerotic; Sulfonylurea Compounds; Thiazolidinediones | 2011 |
Effect of pioglitazone on testosterone in eugonadal men with type 2 diabetes mellitus: a randomized double-blind placebo-controlled study.
Topics: Adult; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Pioglitazone; Sulfonylurea Compounds; Testosterone; Thiazolidinediones | 2013 |
A multicenter, phase III evaluation of the efficacy and safety of a new fixed-dose pioglitazone/glimepiride combination tablet in Japanese patients with type 2 diabetes.
Topics: Asian People; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Diet; Dose-Response Relationship, Drug; Drug Combinations; Exercise; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Lipids; Male; Middle Aged; Pioglitazone; Sulfonylurea Compounds; Thiazolidinediones; Treatment Outcome | 2013 |
Effects of pioglitazone versus glimepiride exposure on hepatocellular fat content in type 2 diabetes.
Topics: Adiponectin; Blood Glucose; Body Mass Index; C-Reactive Protein; Cyclohexanes; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Glycated Hemoglobin; Hepatocytes; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Lipid Metabolism; Lipolysis; Male; Middle Aged; Nateglinide; Phenylalanine; Pioglitazone; Sulfonylurea Compounds; Thiazolidinediones; Treatment Outcome | 2013 |
Pioglitazone decreases asymmetric dimethylarginine levels in patients with impaired glucose tolerance or type 2 diabetes.
Topics: Aged; Aged, 80 and over; Arginine; Diabetes Mellitus, Type 2; Female; Fibronectins; Glucose Intolerance; Humans; Male; Middle Aged; Pioglitazone; Regression Analysis; Sulfonylurea Compounds; Thiazolidinediones | 2013 |
Effects of pioglitazone on visceral fat metabolic activity in impaired glucose tolerance or type 2 diabetes mellitus.
Topics: Administration, Oral; Aged; Body Fat Distribution; Diabetes Mellitus, Type 2; Female; Fluorodeoxyglucose F18; Glucose Intolerance; Humans; Hypoglycemic Agents; Intra-Abdominal Fat; Male; Middle Aged; Multimodal Imaging; Pioglitazone; Positron-Emission Tomography; Subcutaneous Fat; Sulfonylurea Compounds; Thiazolidinediones; Tomography, X-Ray Computed | 2013 |
Randomized, 1-year comparison of three ways to initiate and advance insulin for type 2 diabetes: twice-daily premixed insulin versus basal insulin with either basal-plus one prandial insulin or basal-bolus up to three prandial injections.
Topics: Adult; Aged; Aged, 80 and over; Blood Glucose; Diabetes Mellitus, Type 2; Drug Administration Schedule; Drug Therapy, Combination; Evidence-Based Medicine; Female; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Insulin; Male; Middle Aged; Pioglitazone; Sulfonylurea Compounds; Thiazolidinediones; Treatment Outcome; United States | 2014 |
Pioglitazone decreases coronary artery inflammation in impaired glucose tolerance and diabetes mellitus: evaluation by FDG-PET/CT imaging.
Topics: Aged; Biomarkers; Blood Glucose; C-Reactive Protein; Coronary Angiography; Coronary Artery Disease; Coronary Vessels; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Fluorodeoxyglucose F18; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Japan; Male; Middle Aged; Multimodal Imaging; Pioglitazone; Positron-Emission Tomography; Predictive Value of Tests; Prospective Studies; Radiopharmaceuticals; Sulfonylurea Compounds; Thiazolidinediones; Time Factors; Tomography, X-Ray Computed; Treatment Outcome | 2013 |
Efficacy and safety of hydroxychloroquine in the treatment of type 2 diabetes mellitus: a double blind, randomized comparison with pioglitazone.
Topics: Adolescent; Adult; Aged; Biomarkers; Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Gliclazide; Glycated Hemoglobin; Humans; Hydroxychloroquine; Hypoglycemic Agents; Male; Metformin; Middle Aged; Pioglitazone; Sulfonylurea Compounds; Thiazolidinediones; Treatment Outcome; Young Adult | 2014 |
Comparison of effects of pioglitazone and glimepiride on plasma soluble RAGE and RAGE expression in peripheral mononuclear cells in type 2 diabetes: randomized controlled trial (PioRAGE).
Topics: Adult; Biomarkers; Blood Glucose; Diabetes Mellitus, Type 2; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin Resistance; Japan; Leukocytes, Mononuclear; Male; Middle Aged; Pioglitazone; Receptor for Advanced Glycation End Products; Receptors, Immunologic; Sulfonylurea Compounds; Thiazolidinediones; Time Factors; Treatment Outcome; Young Adult | 2014 |
Efficacy and tolerability of albiglutide versus placebo or pioglitazone over 1 year in people with type 2 diabetes currently taking metformin and glimepiride: HARMONY 5.
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Female; Glucagon-Like Peptide 1; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Pioglitazone; Sulfonylurea Compounds; Thiazolidinediones; Treatment Outcome | 2015 |
Absence of Drug-Drug Interactions Between Luseogliflozin, a Sodium-Glucose Co-transporter-2 Inhibitor, and Various Oral Antidiabetic Drugs in Healthy Japanese Males.
Topics: 1-Deoxynojirimycin; Adult; Antihypertensive Agents; Area Under Curve; Cross-Over Studies; Female; Humans; Hypoglycemic Agents; Japan; Male; Metformin; Middle Aged; Pioglitazone; Pyrazines; Sitagliptin Phosphate; Sorbitol; Sulfonylurea Compounds; Thiazolidinediones; Triazoles | 2015 |
A Pharmacokinetic/Pharmacodynamic Drug-Drug Interaction Study of Tofogliflozin (a New SGLT2 Inhibitor) and Selected Anti-Type 2 Diabetes Mellitus Drugs.
Topics: 1-Deoxynojirimycin; Adult; Benzhydryl Compounds; Cyclohexanes; Diabetes Mellitus, Type 2; Drug Interactions; Glucose; Glucosides; Healthy Volunteers; Humans; Hypoglycemic Agents; Inositol; Male; Metformin; Middle Aged; Nateglinide; Phenylalanine; Pioglitazone; Sitagliptin Phosphate; Sodium-Glucose Transporter 2 Inhibitors; Sulfonylurea Compounds; Thiazolidinediones; Urine; Young Adult | 2016 |
Three-year data from 5 HARMONY phase 3 clinical trials of albiglutide in type 2 diabetes mellitus: Long-term efficacy with or without rescue therapy.
Topics: Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Glycated Hemoglobin; Humans; Hyperglycemia; Hypoglycemic Agents; Insulin Glargine; Male; Pioglitazone; Sitagliptin Phosphate; Sulfonylurea Compounds; Thiazolidinediones; Treatment Outcome | 2017 |
Long-term effect of pioglitazone vs glimepiride on lipoprotein oxidation in patients with type 2 diabetes: a prospective randomized study.
Topics: Aged; Apolipoprotein A-I; Blood Glucose; Cholesterol, HDL; Diabetes Mellitus, Type 2; Female; Glycation End Products, Advanced; Humans; Hypoglycemic Agents; Lipids; Lipoproteins; Lipoproteins, HDL; Lipoproteins, LDL; Male; Middle Aged; Oxidation-Reduction; Pioglitazone; Sulfonylurea Compounds; Thiazolidinediones | 2019 |
Comparison of the effects of three kinds of glucose-lowering drugs on non-alcoholic fatty liver disease in patients with type 2 diabetes: A randomized, open-label, three-arm, active control study.
Topics: Benzhydryl Compounds; Biomarkers; Blood Glucose; Case-Control Studies; Diabetes Mellitus, Type 2; Female; Follow-Up Studies; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Intra-Abdominal Fat; Male; Middle Aged; Non-alcoholic Fatty Liver Disease; Pioglitazone; Prognosis; Prospective Studies; Sodium-Glucose Transporter 2 Inhibitors; Sulfonylurea Compounds | 2020 |
Analysis of pharmacoeconomic value of sitagliptin in the treatment of diabetes mellitus.
Topics: Adult; Aged; Aged, 80 and over; Cost-Benefit Analysis; Diabetes Mellitus; Economics, Pharmaceutical; Female; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Pioglitazone; Sitagliptin Phosphate; Sulfonylurea Compounds | 2021 |
Comparison of Efficacy of Glimepiride, Alogliptin, and Alogliptin-Pioglitazone as the Initial Periods of Therapy in Patients with Poorly Controlled Type 2 Diabetes Mellitus: An Open-Label, Multicenter, Randomized, Controlled Study.
Topics: Autoimmune Diseases; Blood Glucose; Blood Glucose Self-Monitoring; Cholesterol; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Lipids; Lipoproteins, HDL; Metformin; Pioglitazone; Piperidines; Sulfonylurea Compounds; Treatment Outcome; Uracil | 2022 |
36 other study(ies) available for pioglitazone and glimepiride
| Article | Year |
|---|---|
Developing structure-activity relationships for the prediction of hepatotoxicity.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Humans; Structure-Activity Relationship; Tetracyclines; Thiophenes | 2010 |
Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Assay; Biological Transport; Cell Line; Cell Membrane; Chemical and Drug Induced Liver Injury; Cytoplasmic Vesicles; Drug Evaluation, Preclinical; Humans; Liver; Rats; Reproducibility of Results; Spodoptera; Transfection; Xenobiotics | 2010 |
A predictive ligand-based Bayesian model for human drug-induced liver injury.
Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands | 2010 |
FDA-approved drug labeling for the study of drug-induced liver injury.
Topics: Animals; Benchmarking; Biomarkers, Pharmacological; Chemical and Drug Induced Liver Injury; Drug Design; Drug Labeling; Drug-Related Side Effects and Adverse Reactions; Humans; Pharmaceutical Preparations; Reproducibility of Results; United States; United States Food and Drug Administration | 2011 |
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Bile Acids and Salts; Cell Line; Chemical and Drug Induced Liver Injury; Humans; Quantitative Structure-Activity Relationship | 2012 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Human drug-induced liver injury severity is highly associated with dual inhibition of liver mitochondrial function and bile salt export pump.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Chemical and Drug Induced Liver Injury; Humans; Male; Mitochondria, Liver; Rats; Rats, Sprague-Dawley; Severity of Illness Index | 2014 |
Development of a cell viability assay to assess drug metabolite structure-toxicity relationships.
Topics: Adenosine Triphosphate; Benzbromarone; Cell Line; Cell Survival; Chromans; Cytochrome P-450 CYP2C9; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Humans; Pharmaceutical Preparations; Thiazolidinediones; Troglitazone | 2016 |
[Warning signals insulin resistance. Insulin resistance causes not only diabetes].
Topics: Adolescent; Adult; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Glucose Tolerance Test; Humans; Hypoglycemic Agents; Insulin Resistance; Physical Fitness; Pilot Projects; Pioglitazone; Risk Factors; Sulfonylurea Compounds; Thiazolidinediones; Time Factors | 2004 |
Pioglitazone/glimepiride (Duetact) for diabetes.
Topics: Clinical Trials as Topic; Diabetes Mellitus, Type 2; Drug Combinations; Drug Interactions; Humans; Hypoglycemic Agents; Pioglitazone; Sulfonylurea Compounds; Thiazolidinediones | 2007 |
Pioglitazone vs glimepiride and carotid intima-media thickness.
Topics: Atherosclerosis; Carotid Arteries; Diabetes Mellitus, Type 2; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Pioglitazone; Sulfonylurea Compounds; Thiazolidinediones; Tunica Intima | 2007 |
Pioglitazone vs glimepiride and carotid intima-media thickness.
Topics: Albuminuria; Atherosclerosis; Carotid Arteries; Diabetes Mellitus, Type 2; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Pioglitazone; Sulfonylurea Compounds; Thiazolidinediones; Tunica Intima | 2007 |
Does PERISCOPE provide a new perspective on diabetic treatment?
Topics: Atherosclerosis; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Pioglitazone; Sulfonylurea Compounds; Thiazolidinediones | 2008 |
Simultaneous estimation of metformin hydrochloride, pioglitazone hydrochloride, and glimepiride by RP-HPLC in tablet formulation.
Topics: Chromatography, High Pressure Liquid; Hypoglycemic Agents; Metformin; Pioglitazone; Reference Standards; Reproducibility of Results; Sensitivity and Specificity; Sulfonylurea Compounds; Tablets; Thiazolidinediones | 2008 |
Pioglitazone vs glimepiride in the PERISCOPE trial.
Topics: Atherosclerosis; Coronary Angiography; Coronary Artery Disease; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Pioglitazone; Risk; Sulfonylurea Compounds; Thiazolidinediones; Ultrasonography, Interventional | 2008 |
Pioglitazone vs glimepiride in the PERISCOPE trial.
Topics: Atherosclerosis; Coronary Artery Disease; Diabetes Mellitus, Type 2; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypoglycemic Agents; Pioglitazone; Sulfonylurea Compounds; Thiazolidinediones | 2008 |
Oral glyburide, but not glimepiride, blocks the infarct-size limiting effects of pioglitazone.
Topics: Administration, Oral; Animals; Body Weight; Coronary Vessels; Data Interpretation, Statistical; Decanoic Acids; Diabetes Mellitus; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Glyburide; Hydroxy Acids; Injections, Intravenous; Intubation, Gastrointestinal; KATP Channels; Ligation; Mitochondria, Heart; Myocardial Infarction; Myocardial Ischemia; Pioglitazone; Rats; Rats, Sprague-Dawley; Sulfonylurea Compounds; Thiazolidinediones; Ventricular Remodeling | 2008 |
Simultaneous determination of pioglitazone and glimepiride in bulk drug and pharmaceutical dosage form by RP-HPLC method.
Topics: Calibration; Chromatography, High Pressure Liquid; Dosage Forms; Drug Combinations; Hypoglycemic Agents; Pioglitazone; Reproducibility of Results; Sulfonylurea Compounds; Technology, Pharmaceutical; Thiazolidinediones | 2008 |
Lost in translation: modulation of the metabolic-functional relation in the diabetic human heart.
Topics: Animals; Diabetes Complications; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Fatty Acids; Female; Heart; Humans; Hypoglycemic Agents; Insulin Resistance; Male; Metabolic Syndrome; Metformin; Myocardium; Oxidation-Reduction; Pioglitazone; PPAR alpha; Sulfonylurea Compounds; Thiazolidinediones; Ventricular Dysfunction, Left | 2009 |
Successful switch from insulin therapy to treatment with pioglitazone in type 2 diabetes patients with residual beta-cell function: results from the PioSwitch study.
Topics: Adult; Aged; Biomarkers; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Insulin; Male; Middle Aged; Pilot Projects; Pioglitazone; Prospective Studies; Sulfonylurea Compounds; Thiazolidinediones; Treatment Outcome | 2009 |
Increased frequency of micronuclei in diabetes mellitus patients using pioglitazone and glimepiride in combination.
Topics: Adult; Aged; Diabetes Mellitus, Type 2; DNA Damage; Drug Therapy, Combination; Epithelial Cells; Female; Genetic Markers; Humans; Hypoglycemic Agents; Male; Micronucleus Tests; Middle Aged; Pioglitazone; Sulfonylurea Compounds; Thiazolidinediones | 2010 |
Novel liquid chromatographic method for simultaneous estimation of pioglitazone and glimepiride in rat plasma by solid phase extraction: application to preclinical pharmacokinetic studies.
Topics: Animals; Area Under Curve; Calibration; Chromatography, High Pressure Liquid; Drug Evaluation, Preclinical; Drug Interactions; Half-Life; Hypoglycemic Agents; Male; Pioglitazone; Rats; Rats, Wistar; Reference Standards; Reproducibility of Results; Solid Phase Extraction; Spectrophotometry, Ultraviolet; Sulfonylurea Compounds; Thiazolidinediones | 2011 |
Imaging inflammatory changes in atherosclerosis multimodal imaging hitting stride.
Topics: Animals; Anti-Inflammatory Agents; Aorta; Aortic Diseases; Aortography; Atherosclerosis; Carotid Artery Diseases; Contrast Media; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Fluorodeoxyglucose F18; Glucose Intolerance; Humans; Hypoglycemic Agents; Inflammation; Magnetic Resonance Angiography; Male; Multimodal Imaging; Pioglitazone; Positron-Emission Tomography; Radiopharmaceuticals; Sulfonylurea Compounds; Thiazolidinediones; Tomography, X-Ray Computed | 2011 |
Imaging of pharmacologic intervention decoding therapeutic mechanism or defining effectiveness?
Topics: Anti-Inflammatory Agents; Aortic Diseases; Aortography; Carotid Artery Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Fluorodeoxyglucose F18; Glucose Intolerance; Humans; Hypoglycemic Agents; Inflammation; Male; Multimodal Imaging; Pioglitazone; Positron-Emission Tomography; Radiopharmaceuticals; Sulfonylurea Compounds; Thiazolidinediones; Tomography, X-Ray Computed | 2011 |
New formulation approaches to improve solubility and drug release from fixed dose combinations: case examples pioglitazone/glimepiride and ezetimibe/simvastatin.
Topics: Azetidines; Chemistry, Pharmaceutical; Drug Combinations; Ezetimibe, Simvastatin Drug Combination; Pioglitazone; Simvastatin; Solubility; Sulfonylurea Compounds; Thiazolidinediones; X-Ray Diffraction | 2013 |
Simultaneous determination of glimepiride and pioglitazone in human plasma by liquid chromatography-tandem mass spectrometry and its application to pharmacokinetic study.
Topics: Adult; Chromatography, High Pressure Liquid; Humans; Linear Models; Male; Pioglitazone; Reproducibility of Results; Sensitivity and Specificity; Sulfonylurea Compounds; Tandem Mass Spectrometry; Thiazolidinediones; Young Adult | 2014 |
[Fixed-dose combination].
Topics: Diabetes Mellitus, Type 2; Drug Therapy, Combination; Humans; Hypoglycemic Agents; Inositol; Isoindoles; Metformin; Pioglitazone; Piperidines; Sulfonylurea Compounds; Thiazolidinediones; Uracil | 2015 |
Simultaneous Determination of Metformin, Glipizide, Repaglinide, and Glimepiride or Metformin and Pioglitazone by a Validated LC Method: Application in the Presence of Metformin Impurity (1-Cyanoguanidine).
Topics: Carbamates; Chromatography, High Pressure Liquid; Drug Contamination; Glipizide; Guanidines; Hypoglycemic Agents; Metformin; Pioglitazone; Piperidines; Sulfonylurea Compounds; Thiazolidinediones | 2016 |
Simultaneous spectrophotometric determination of glimepiride and pioglitazone in binary mixture and combined dosage form using chemometric-assisted techniques.
Topics: Drug Combinations; Linear Models; Pioglitazone; Reproducibility of Results; Spectrophotometry, Ultraviolet; Sulfonylurea Compounds; Thiazolidinediones | 2017 |
Absorbance detector for high performance liquid chromatography based on a deep-UV light-emitting diode at 235nm.
Topics: Chromatography, High Pressure Liquid; Hypoglycemic Agents; Pioglitazone; Sulfonylurea Compounds; Thiazolidinediones; Ultraviolet Rays | 2017 |
Applications of Fourier transform infrared spectroscopic method for simultaneous quantitation of some hypoglycemic drugs in their binary mixtures.
Topics: Hypoglycemic Agents; Limit of Detection; Metformin; Pioglitazone; Spectrophotometry, Ultraviolet; Spectroscopy, Fourier Transform Infrared; Sulfonylurea Compounds; Vildagliptin | 2019 |
Potentiometric CheqSol and standardized shake-flask solubility methods are complimentary tools in physicochemical profiling.
Topics: Cyclobutanes; Hydrogen-Ion Concentration; Pharmaceutical Preparations; Pioglitazone; Potentiometry; Solubility; Sulfonylurea Compounds; Technology, Pharmaceutical | 2020 |
A possible alternative therapy for type 2 diabetes using Myristica fragrans Houtt in combination with glimepiride: in vivo evaluation and in silico support.
Topics: Alloxan; Animals; Diabetes Mellitus, Type 2; Disease Models, Animal; Drug Therapy, Combination; Female; Glucose; Humans; Hypoglycemic Agents; Lignans; Male; Mice; Molecular Docking Simulation; Molecular Dynamics Simulation; Myristica; Pioglitazone; Plant Extracts; PPAR alpha; PPAR gamma; Sulfonylurea Compounds; Time Factors | 2020 |
Spectrophotometric methods for determination of glimepiride and pioglitazone hydrochloride mixture and application in their pharmaceutical formulation.
Topics: Drug Compounding; Pioglitazone; Reproducibility of Results; Spectrophotometry; Sulfonylurea Compounds | 2022 |
Deduction of the operable design space of RP-HPLC technique for the simultaneous estimation of metformin, pioglitazone, and glimepiride.
Topics: Chromatography, High Pressure Liquid; Humans; Hypoglycemic Agents; Metformin; Pioglitazone; Thiazolidinediones | 2023 |
Analysis of Hypoglycemic Drugs by Liquid Chromatography-Tandem Mass Spectrometry.
Topics: Chlorpropamide; Chromatography, High Pressure Liquid; Chromatography, Liquid; Glipizide; Glyburide; Humans; Hypoglycemic Agents; Nateglinide; Pioglitazone; Rosiglitazone; Spectrometry, Mass, Electrospray Ionization; Tandem Mass Spectrometry; Tolazamide; Tolbutamide | 2024 |